Shares of Tenax Therapeutics jumped +7.6% to $2.13 on a broadly weaker market day as two catalysts converged: CEO Chris Giordano took the stage at the 12th Annual Cantor Fitzgerald Global Healthcare Conference to argue that its Phase 3 LEVEL trial was "more a lesson in patient selection than a verdict" on its lead drug, levosimendan . Meanwhile, filings show ADAR1 Capital Management now holds 6,524,151 shares after a series of aggressive purchases — an unusual vote of confidence in a stock down 84% year-to-date.
• A Big Investor Keeps Doubling Down Despite the Wreckage
ADAR1, already a 10%-plus owner, bought another 900,000 shares on September 3 at prices between $1.78–$1.80, spending roughly $1.6 million . Combined with approximately $1.81 million deployed across August 20–24 , the fund has poured over $3.4 million into TENX in under three weeks. SEC filings peg its stake at roughly 14% of shares outstanding . That kind of concentrated buying from a single fund can prop up a micro-cap stock, but it also means ADAR1's own exit would be difficult without moving the price.
• The Drug's Main Study Failed — Management Says It Learned Why
The Phase 3 LEVEL trial of oral levosimendan — a heart-and-lung drug targeting a form of pulmonary hypertension with no approved treatment — missed its primary endpoint . The improvement in walking distance versus placebo was just 3.5 meters . But in sicker patients, the drug showed a 26.3-meter improvement (p = 0.0112) and a 47% drop in a key cardiac-stress marker . Tenax now argues a follow-up trial enrolling only these higher-risk patients could succeed — though management concedes the subgroup findings are not statistically adjusted, and a strong subgroup inside a failed trial "cannot substitute automatically for prospective confirmation."
• Wall Street Analysts Are Strikingly Bullish — But Caveats Abound
Evercore ISI initiated coverage with an Outperform rating and a $39 price target, assigning a 50% probability of clinical success . Cantor Fitzgerald reiterated Overweight with a $35 target . Those targets sit roughly 16–18x the current price — a gap that reflects how binary this bet is. If the next trial works, enormous upside; if it stumbles again, the stock has little fundamental floor.
• The Real Question: Cash Runway vs. Clinical Timeline
TENX has virtually no revenue — its price-to-sales ratio "stands near zero" . The company must fund a second Phase 3 study, meaning further share sales that would dilute existing investors are likely. With shares already down ~90% from their pre-trial peak , any stumble in trial design or financing could push the stock toward its 52-week low of $1.31.